In Brief: Focal
This article was originally published in The Gray Sheet
Focal: Inks collaborative product development agreement with Chiron and Ciba Pharmaceuticals under which Chiron and Ciba restenosis drug candidates will be combined with Focal's development-stage biodegradable gel drug delivery technology. Focal says the agreement will provide "research funding, milestone fees and future royalty payments on product sales." Focal's light-activated, adhering gel is designed to be deposited locally via a fiber-optic, double-balloon catheter that is under development. After placement, the drug combined with the gel would slowly release as the gel degrades, Focal explains...
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.